<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Imipenem and cilastatin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Imipenem and cilastatin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Imipenem and cilastatin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11382" href="/d/html/11382.html" rel="external">see "Imipenem and cilastatin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13375" href="/d/html/13375.html" rel="external">see "Imipenem and cilastatin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F182065"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Primaxin I.V.</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912095"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imipenem and Cilastatin for Injection;</li>
<li>Imipenem and Cilastatin for Injection, USP;</li>
<li>Primaxin;</li>
<li>RAN-Imipenem-Cilastatin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F182088"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Carbapenem</li></ul></div>
<div class="block doa drugH1Div" id="F182068"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses presented are based on <b>imipenem</b> component. Infusion method: Dosing is presented based on the traditional infusion method over 30 minutes, unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>An extended infusion strategy has a greater likelihood of attaining pharmacokinetic/pharmacodynamic targets and may offer clinical benefit in patients with severe infections or less susceptible pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28919718','lexi-content-ref-25727953','lexi-content-ref-30310294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28919718','lexi-content-ref-25727953','lexi-content-ref-30310294'])">Ref</a></span>). Some experts recommend extended infusion (ie, 500 mg every 6 hours over 3 hours) for treatment of infections caused by certain resistant organisms (eg, carbapenem-resistant <i>Acinetobacter baumannii, </i>carbapenem-resistant Enterobacterales) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traditional intermittent infusion method:</i>
<b>IV:</b> 500 mg every 6 hours infused over 30 minutes <b>or</b> 1 g every 6 to 8 hours infused over 40 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended infusion method (off label):</i>
<b> IV:</b> 500 mg to 1 g every 6 hours infused over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28919718','lexi-content-ref-30310294','lexi-content-ref-25216543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28919718','lexi-content-ref-30310294','lexi-content-ref-25216543'])">Ref</a></span>). May give a loading dose of 500 mg to 1 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25216543','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25216543','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (gram-negative bacteremia):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For empiric therapy of known or suspected gram-negative organisms (including <i>Pseudomonas aeruginosa</i>) or pathogen-directed therapy for organisms resistant to other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31599774','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31599774','lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg every 6 hours (IDSA [Mermel 2009]); for empiric therapy in patients with neutropenia, severe burns, sepsis, or septic shock, give as part of an appropriate combination regimen. <b>Note:</b> For critical illness or infection with an organism with an elevated minimum inhibitory concentration, some experts prefer the extended infusion method (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.1','lexi-content-ref-Kanj.2','lexi-content-ref-Moehring.2020a','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.1','lexi-content-ref-Kanj.2','lexi-content-ref-Moehring.2020a','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Usual duration is 7 to 14 days depending on the source, pathogen, extent of infection, and clinical response; a 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2020a','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2020a','lexi-content-ref-30535100'])">Ref</a></span>). Longer durations may be warranted in immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-28500792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-28500792'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For empiric or targeted treatment of <i>P. aeruginosa</i> or other gram-negative bacilli (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25102221','lexi-content-ref-simon.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25102221','lexi-content-ref-simon.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg to 1 g every 6 hours, most often given as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25102221','lexi-content-ref-19729669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25102221','lexi-content-ref-19729669'])">Ref</a></span>). <b>Note:</b> Some experts use the extended infusion method to optimize exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-simon.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-simon.2021'])">Ref</a></span>). Duration is usually 10 to 14 days, depending on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-34469706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-34469706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> As a component of empiric therapy in patients at risk for <i>P. aeruginosa</i> (eg, significant water exposure, macerated wound) or other gram-negative bacteria resistant to other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg every 6 hours. Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8075257','lexi-content-ref-22619242','lexi-content-ref-19832720','lexi-content-ref-Weintrob.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8075257','lexi-content-ref-22619242','lexi-content-ref-19832720','lexi-content-ref-Weintrob.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment: Note: </b>For treatment of endocarditis caused by resistant gram-negative bacilli, including <i>Pseudomonas</i> species (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>500 mg every 6 hours <b>or</b> 1 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>), as part of an appropriate combination regimen, for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a9704e3-3c04-4560-bf3b-ab333b8ed84b">Intra-abdominal infection, health care–associated or high-risk community-acquired infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, health care–associated or high-risk community-acquired infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For community-acquired infection, reserve for patients who cannot tolerate a beta-lactam or are at risk for infection with an extended-spectrum beta-lactamase (ESBL)–producing organism (eg, known colonization or prior infection with an ESBL-producing organism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2023','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2023','lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute uncomplicated:</i>
<b> IV:</b> 500 mg every 6 hours <b>or</b> 1 g every 8 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infection (eg, cholangitis, complicated cholecystitis, appendicitis, diverticulitis, intra-abdominal abscess): </i>
<b>IV:</b> 500 mg every 6 hours or 1 g every 8 hours. Total duration (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2023','lexi-content-ref-Pemberton.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2023','lexi-content-ref-Pemberton.2023'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>). <b>Note:</b> For patients who are critically ill or at high risk for infection with drug-resistant pathogens, some experts favor the extended infusion method (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2023','lexi-content-ref-28484510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2023','lexi-content-ref-28484510'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8713978a-d495-46cd-89da-072b22dab991">Melioidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melioidosis (<i>Burkholderia pseudomallei</i></b>
<b>infection) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial intensive therapy:</i>
<b>IV:</b> 25 mg/kg up to 1 g every 6 to 8 hours for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14516149','lexi-content-ref-10476746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14516149','lexi-content-ref-10476746'])">Ref</a></span>); a longer duration may be necessary depending on disease severity and site of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14516149','lexi-content-ref-16547571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14516149','lexi-content-ref-16547571'])">Ref</a></span>). Some experts prefer meropenem over imipenem (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Currie.2021','lexi-content-ref-16547571','lexi-content-ref-29388572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Currie.2021','lexi-content-ref-16547571','lexi-content-ref-29388572'])">Ref</a></span>) and recommend adding sulfamethoxazole/trimethoprim for patients with focal disease of the CNS, prostate, bone, joint, skin, or soft tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Currie.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Currie.2021'])">Ref</a></span>). <b>Note:</b> Following the course of parenteral therapy, eradication therapy with oral antibiotics for ≥12 weeks is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14516149','lexi-content-ref-16547571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14516149','lexi-content-ref-16547571'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous, rapidly growing) infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg to 1 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077618','lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077618','lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>); some experts also suggest these doses up to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32628747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32628747'])">Ref</a></span>). Give as part of an appropriate combination regimen. The optimal duration of therapy is unknown but generally the duration of parenteral therapy is 2 to 12 weeks depending on pathogen, severity of infection, and other patient-specific factors, followed by long-term oral maintenance therapy; consult an infectious diseases specialist for specific recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077618','lexi-content-ref-32628747','lexi-content-ref-29054853','lexi-content-ref-26666259','lexi-content-ref-Griffith.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077618','lexi-content-ref-32628747','lexi-content-ref-29054853','lexi-content-ref-26666259','lexi-content-ref-Griffith.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f14f5ce2-bd10-40b4-9131-53adc589c5db">Neutropenic enterocolitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic enterocolitis (typhlitis) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients colonized or infected with a resistant gram-negative bacillus, such as an ESBL-producing organism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WongKeeSong.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WongKeeSong.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg every 6 hours; continue until neutropenia is resolved and clinically improved, then switch to oral antibiotics. The total duration of antibiotics is generally 14 days following recovery from neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-WongKeeSong.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-WongKeeSong.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e55b896-e3d1-46d2-a9b0-f54546c753e2">Neutropenic fever, high-risk cancer patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, high-risk cancer patients (empiric therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> High-risk patients are those expected to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days <b>or</b> an ANC ≤100 cells/mm<sup>3</sup> for any expected duration if there are ongoing comorbidities (eg, sepsis, mucositis, significant hepatic or renal dysfunction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>); some experts use an ANC cutoff of &lt;500 cells/mm<sup>3</sup> to define high-risk patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344285'])">Ref</a></span>) until afebrile for ≥48 hours and neutropenia has resolved (ANC ≥500 cells/mm<sup>3</sup> and increasing); if specific infection is identified, give for standard duration if longer than the duration of neutropenia. Additional agent(s) may be needed depending on clinical status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-Wingard.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-Wingard.2020'])">Ref</a></span>). Some experts prefer the extended infusion method, particularly in patients who are critically ill (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25727953','lexi-content-ref-Moehring.2020b','lexi-content-ref-34599691','lexi-content-ref-Wingard.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25727953','lexi-content-ref-Moehring.2020b','lexi-content-ref-34599691','lexi-content-ref-Wingard.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8327f937-2b46-49ac-86e4-8b68d5d1b357">Nocardiosis, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nocardiosis, severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Due to concerns for resistance, susceptibility testing should be performed on isolates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg every 6 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.2020'])">Ref</a></span>). Consult an infectious diseases specialist for specific treatment recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Prolonged treatment is required (range: 6 months to ≥1 year [at least several weeks of parenteral therapy followed by oral therapy]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30658169','lexi-content-ref-Spelman.2020','lexi-content-ref-22469352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30658169','lexi-content-ref-Spelman.2020','lexi-content-ref-22469352'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (patients receiving peritoneal dialysis) (alternative agent for pathogens resistant to other agents) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Intraperitoneal administration is preferred to IV administration unless the patient has sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>). Consider a 25% dose increase (for intermittent or continuous dosing) in patients with significant residual renal function (urine output &gt;100 mL/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851','lexi-content-ref-20628102','lexi-content-ref-29987068','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851','lexi-content-ref-20628102','lexi-content-ref-29987068','lexi-content-ref-29987069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent (every other exchange):</i>
<b>Intraperitoneal:</b> 500 mg added to the dialysate solution with every other exchange; allow to dwell ≥6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7612739','lexi-content-ref-27282851','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7612739','lexi-content-ref-27282851','lexi-content-ref-29987069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous (with every exchange) (dose is per liter of dialysate):</i>
<b>Intraperitoneal:</b> Loading dose: 250 mg/<b>L</b> with first exchange of dialysate; maintenance dose: 50 mg/<b>L</b> with each subsequent exchange of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851','lexi-content-ref-7977477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851','lexi-content-ref-7977477'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> ≥3 weeks for patients with adequate clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burkart.2022','lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burkart.2022','lexi-content-ref-27282851'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Community-acquired pneumonia:</b></i>For empiric therapy of inpatients at risk of infection with a multidrug-resistant (MDR) gram-negative pathogen(s), including <i>P. aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 500 mg every 6 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is a minimum of 5 days; a longer course may be required for patients with an immunocompromising condition, severe or complicated infection, or for <i>P. aeruginosa</i> infection. Patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-32561442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-32561442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hospital-acquired or ventilator-associated pneumonia:</b></i> For empiric therapy (often as part of an appropriate combination regimen) or pathogen-specific therapy; reserve for patients with or at risk for MDR gram-negative pathogen(s) (eg, <i>P. aeruginosa, Acinetobacter</i> spp.) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31599774','lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31599774','lexi-content-ref-27418577'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 500 mg every 6 hours. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>). <b>Note:</b> Some experts prefer extended infusion for critical illness or when treating a susceptible organism with an elevated minimum inhibitory concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28919718','lexi-content-ref-Klompas.2022','lexi-content-ref-Moehring.2020b','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28919718','lexi-content-ref-Klompas.2022','lexi-content-ref-Moehring.2020b','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a74533c8-554a-440e-8601-6b5e9cffeae7">Sepsis and septic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis and septic shock (broad-spectrum empiric therapy, including <i>P. aeruginosa</i>) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>500 mg every 6 hours <b>or</b> 1 g every 8 hours in combination with other appropriate agent(s) when applicable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25727953','lexi-content-ref-Moehring.2020a','lexi-content-ref-Schmidt.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25727953','lexi-content-ref-Moehring.2020a','lexi-content-ref-Schmidt.2020'])">Ref</a></span>). Initiate therapy as soon as possible once there is recognition of sepsis or septic shock. Duration is dependent on underlying source and patient response; short courses are preferred, when appropriate. Discontinue if a noninfectious etiology is identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>). <b>Note:</b> Some experts prefer the extended infusion method (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2020b','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2020b','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5389b037-d8ce-48e2-98b3-f8bb5a208a34">Skin and soft tissue infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients with necrotizing infections, select surgical site infections (intestinal, GU tract), or patients with or at risk for pathogens resistant to other agents, including <i>P. aeruginosa</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31599774','lexi-content-ref-19273670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31599774','lexi-content-ref-19273670'])">Ref</a></span>). Often used as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Kanj.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Kanj.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Necrotizing infection (off-label use): </i>
<b>IV:</b> 1 g every 6 to 8 hours. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for ≥48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Kanj.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Kanj.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-necrotizing infection: </i>
<b>IV:</b> 500 mg every 6 hours. Usual duration (including oral step-down therapy) is 5 to 14 days based on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Kanj.3','lexi-content-ref-7716590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Kanj.3','lexi-content-ref-7716590'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for critically ill patients or for patients with risk factor(s) for MDR pathogens, including ESBL-producing organisms and <i>P. aeruginosa</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.2022','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.2022','lexi-content-ref-35439291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>500 mg every 6 hours. Switch to an appropriate oral regimen once symptoms improve if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.2022','lexi-content-ref-28575389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.2022','lexi-content-ref-28575389'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991483"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Doses based on <b>imipenem</b> component.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Altered kidney function: IV:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="4">
<p style="text-indent:0em;text-align:center;">
<b>Imipenem Dosage Adjustments (Intermittent Infusion Method) for Altered Kidney Function<sup>a,b</sup></b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">CrCl<sup>c</sup> (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">If the usual recommended dose is 500 mg every 6 hours</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">If the usual recommended dose is 1 g every 8 hours</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">If the usual recommended dose is 1 g every 6 hours<sup>d</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Recommended doses are based on expert opinion derived from Gibson 1985; Verbist 1986; Yoshizawa 2012. <b>Note:</b> Recommendations may vary considerably compared to the manufacturer’s labeling.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Patients with acute kidney injury may have increased non-renal clearance compared to patients with chronic kidney disease. Monitor patients closely and consider an increased dose or alternative agent if the patient does not respond to therapy (Mueller 1993).</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>CrCl determined using Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Designed to achieve a pharmacodynamic target of ≥40% <i>f</i>T &gt; MIC for an MIC of 4 mg/L (Yoshizawa 2012).</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>e </sup>The more frequent dosing regimen may decrease the risk of toxicity in this population (Yoshizawa 2012).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">≥60 to &lt;130</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">≥30 to &lt;60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">250 mg every 6 hours <b>or</b> 500 mg every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mg every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mg every 6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">≥15 to &lt;30<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">250 mg every 8 hours <b>or</b> 500 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">250 mg every 8 hours <b>or</b> 500 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">250 mg every 6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15</p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Do not administer imipenem/cilastatin unless hemodialysis is instituted within 48 hours.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (55% imipenem, 63% cilastatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1929334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1929334'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 250 to 500 mg every 12 hours, depending on infection type and severity. When scheduled dosing falls on dialysis days, one of the doses should be scheduled to be given after dialysis, if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2211452','lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2211452','lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IV:</b> 250 to 500 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2055813','lexi-content-ref-3377464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2055813','lexi-content-ref-3377464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g as a single dose, followed by 250 mg every 6 hours or 500 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-16163635','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-16163635','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>: 500 mg to 1 g as a single dose, followed by 250 mg every 6 hours <b>or</b> 500 mg every 8 hours with one of the doses scheduled to be given after PIRRT on PIRRT days when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended doses may reduce risk of neurotoxicity but may not achieve PK/PD targets. Monte Carlo simulations suggest doses of 750 mg every 6 hours or 1 g every 8 hours are necessary to achieve a PK/PD target of <i>f</i>T 4 × MIC &gt;40% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26919659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26919659'])">Ref</a></span>); however, risk of neurotoxicity (eg, seizures) is significantly higher. Therefore, use of an alternative antimicrobial agent may be preferred.</p></div>
<div class="block doha drugH1Div" id="F50988831"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F182069"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F182081"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13375" href="/d/html/13375.html" rel="external">see "Imipenem and cilastatin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage recommendations are based on <b>imipenem</b> component.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IV: 15 to 25 mg/kg/dose every 6 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Doses on the higher end of the range are recommended for infections caused by susceptible <i>Pseudomonas aeruginosa</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30962334','lexi-content-ref-AAP.2021','lexi-content-ref-23676856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30962334','lexi-content-ref-AAP.2021','lexi-content-ref-23676856'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation:</b> Infants, Children, and Adolescents: IV: 25 mg/kg/dose every 6 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11106223','lexi-content-ref-22911974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11106223','lexi-content-ref-22911974'])">Ref</a></span>). Treatment duration varies and is dependent on patient-specific factors including response to therapy; typical duration is 10 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 15 to 25 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose. Duration dependent upon age, source of infection, and surgical status. Typical duration is 4 to 7 days unless source control inadequate; in some circumstances (ie, acute or gangrenous appendicitis without perforation managed with surgery), therapy should be limited to ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8713978a-d495-46cd-89da-072b22dab991">Melioidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melioidosis (</b>
<b>
<i>Burkholderia pseudomallei</i> infection):</b> Infants, Children, and Adolescents: IV: Initial: 25 mg/kg/dose every 6 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14516149','lexi-content-ref-22970946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14516149','lexi-content-ref-22970946'])">Ref</a></span>). Duration of parenteral therapy for initial intensive therapy is typically ≥14 days, though a longer duration may be necessary depending on disease severity and site of infection; after initial intensive therapy, transition to oral eradication therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32986699','lexi-content-ref-29388572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32986699','lexi-content-ref-29388572'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7484de1-b3ea-45f3-b62f-088da5bc9e10">Mycobacterial infection, pulmonary infection in patients with cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) infection, pulmonary infection in patients with cystic fibrosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 15 to 20 mg/kg/dose every 12 hours as part of an appropriate combination regimen; maximum dose: 1,000 mg/dose. The duration of parenteral therapy is generally 3 to 12 weeks depending on clinical response, followed by transition to oral and/or inhaled therapy; total treatment duration is ≥12 months after culture conversion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26666259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c3ec306-657e-4501-9d5f-691c697a0b55">Neutropenic fever, empiric treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric treatment: </b>Limited data available: Children and Adolescents: IV: 15 to 25 mg/kg/dose every 6 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17366527','lexi-content-ref-20104991','lexi-content-ref-1766707','lexi-content-ref-19744230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17366527','lexi-content-ref-20104991','lexi-content-ref-1766707','lexi-content-ref-19744230'])">Ref</a></span>). Duration of empiric therapy is typically until blood cultures are negative at 48 hours and patient has been clinically well and afebrile ≥24 hours with evidence of marrow recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36689694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36689694'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis):</b> Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 250 mg per liter of dialysate; maintenance dose: 50 mg per liter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113723"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Renally adjusted dose recommendations are based on doses of 15 to 25 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>). The manufacturer does not recommend use in pediatric patients weighing &lt;30 kg with impaired renal function (not defined) due to lack of data.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: IV: Administer 7 to 13 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: IV: Administer 7.5 to 12.5 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: IV: Administer 7.5 to 12.5 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Moderately dialyzable (20% to 50%).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 7.5 to 12.5 mg/kg/dose every 24 hours (administer after hemodialysis on dialysis days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis (PD): </b>Infants, Children, and Adolescents: IV: 7.5 to 12.5 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Infants, Children, and Adolescents: IV: 7 to 13 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51113724"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F182034"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (infants and children 3 months to 12 years: 18%; neonates and infants &lt;3 months: 2%), decreased hemoglobin (infants and children 3 months to 12 years: 15%), eosinophilia (neonates, infants, and children to 12 years: 9% to 13%), thrombocythemia (infants and children 3 months to 12 years: 13%; neonates and infants &lt;3 months: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum AST (infants and children 3 months to 12 years: 18%; neonates and infants &lt;3 months: 6%), increased serum ALT (infants and children 3 months to 12 years: 11%; neonates and infants &lt;3 months: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Phlebitis (2% to 3%), tachycardia (neonates and infants ≤3 months: 2%; adults &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Seizure (neonates and infants ≤3 months: 6%; adults &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (neonates, infants, and children to 12 years: 3% to 4%; adults 2%), nausea (2%), oral candidiasis (neonates and infants ≤3 months: 2%), vomiting (≤1% to 2%), gastroenteritis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (infants and children 3 months to 12 years: 8%), urine discoloration (≤1%), oliguria (neonates and infants ≤3 months: 2%; adults &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (infants and children 3 months to 12 years: 3%; adults &lt;1%), decreased platelet count (neonates and infants &lt;3 months: 2%), increased hematocrit (neonates and infants &lt;3 months: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (neonates and infants &lt;3 months: 3%), increased serum bilirubin (neonates and infants &lt;3 months: 3%), decreased serum bilirubin (neonates and infants &lt;3 months: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Irritation at injection site (infants, children, and adolescents 3 months to 16 years: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (neonates and infants &lt;3 months: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Abdominal pain, acute renal failure, agitation, agranulocytosis, anaphylaxis, angioedema, back pain (thoracic spinal), basophilia, bilirubinuria, bone marrow depression, brain disease, candidiasis, casts in urine, change in prothrombin time, chest discomfort, <i>Clostridioides difficile</i>-associated diarrhea, confusion, cyanosis, decreased serum sodium, dental discoloration, dizziness, drowsiness, drug fever, dysgeusia, dyskinesia, dyspnea, erythema at injection site, erythema multiforme, fever, flushing, glossitis, hallucination, headache, hearing loss, heartburn, hematuria, hemolytic anemia, hemorrhagic colitis, hepatic failure, hepatitis (including fulminant onset), hyperchloremia, hyperhidrosis, hypersensitivity, hyperventilation, hypotension, increased blood urea nitrogen, increased lactate dehydrogenase, increased monocytes, increased serum potassium, increased urinary urobilinogen, induration at injection site, injection site infection, jaundice, leukocytosis, leukocyturia, leukopenia, lymphocytosis, myoclonus, neutropenia, pain at injection site, palpitations, pancytopenia, paresthesia, polyarthralgia, polyuria, positive direct Coombs' test, pruritus, pruritus vulvae, pseudomembranous colitis, pseudomonas infection (resistant P. aeruginosa), psychiatric disturbances, sialorrhea, skin changes (texture), sore throat, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, tongue changes (papillar hypertrophy), tongue discoloration, toxic epidermal necrolysis, tremor, urticaria, vertigo, weakness</p></div>
<div class="block coi drugH1Div" id="F182050"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to imipenem/cilastatin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F182031"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. However, there have been reports of adverse CNS effects in patients who had no recognized or documented underlying CNS disorder or compromised renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity/anaphylactic reactions have been reported, including fatalities; may be more common in patients with a history of sensitivity to multiple allergens. Patients with a history of penicillin hypersensitivity may experience severe hypersensitivity reactions when treated with other beta-lactams; carefully inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams, and other allergens. Serious anaphylactic reactions require immediate discontinuation and supportive care as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate to severe renal dysfunction. Increased seizure risk has been reported in patients with significant renal dysfunction. Do not use in patients with CrCl ≤15 mL/minute unless hemodialysis is instituted within 48 hours. For patients on hemodialysis, use is recommended only when the benefit outweighs the potential risk of seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Valproic acid and derivatives: Carbapenems, including imipenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not recommended in pediatric CNS infections due to seizure potential.</p></div>
<div class="block foc drugH1Div" id="F182043"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Primaxin I.V.: Imipenem 500 mg and cilastatin 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution (preservative free):</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Imipenem 250 mg and cilastatin 250 mg; Imipenem 500 mg and cilastatin 500 mg</p></div>
<div class="block geq drugH1Div" id="F182027"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323195"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Imipenem-Cilastatin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $7.80 - $17.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $15.00 - $35.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Primaxin IV Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500-500 mg (per each): $39.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54175124"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Primaxin: imipenem 500 mg and cilastatin 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;">RAN-Imipenem-Cilastatin: imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg</p></div>
<div class="block adm drugH1Div" id="F182047"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV infusion only; do not administer IV push. Infuse doses ≤500 mg over 20 to 30 minutes; infuse doses &gt;500 mg over 40 to 60 minutes. If nausea and/or vomiting occur during administration, decrease the rate of IV infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-infusion administration (off-label method): Administer over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28919718','lexi-content-ref-25216543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28919718','lexi-content-ref-25216543'])">Ref</a></span>). <b>Note:</b> Must consider imipenem/cilastatin limited room temperature stability if using extended infusions.</p></div>
<div class="block admp drugH1Div" id="F52613036"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer by IV intermittent infusion; doses ≤500 mg may be infused over 20 to 30 minutes; doses &gt;500 mg should be infused over 40 to 60 minutes. If nausea and/or vomiting occur during administration, decrease the rate of IV infusion.</p></div>
<div class="block use drugH1Div" id="F182046"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (gram-negative bacteremia): </b>Treatment of bloodstream infection caused by <i>Enterococcus faecalis, Staphylococcus aureus </i>(penicillinase-producing), <i>Escherichia coli, Klebsiella</i> species, <i>Pseudomonas aeruginosa,</i>
<i>Serratia</i> species, <i>Enterobacter</i> species, and <i>Bacteroides</i> species (including <i>Bacteroides fragilis</i>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone and joint infections: </b>Treatment of bone and joint infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>Staphylococcus epidermidis, Enterobacter</i> species, and <i>P. aeruginosa.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis:</b> Treatment of endocarditis caused by susceptible strains of <i>S. aureus</i> (penicillinase-producing isolates). <b>Note:</b> Clinical practice guidelines do not recommend imipenem/cilastatin for endocarditis due to <i>S. aureus</i>; however, it may be useful, as part of an appropriate combination regimen, for treatment of endocarditis caused by resistant gram-negative bacilli, including <i>Pseudomonas</i> species (AHA [Baddour 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gynecologic infections: </b>Treatment of gynecologic infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>S. epidermidis, Streptococcus agalactiae</i> (group B streptococci), <i>E. coli</i>, <i>Klebsiella </i>species, <i>Proteus </i>species, <i>Enterobacter</i> species, <i>Bifidobacterium</i> species, <i>Bacteroides</i> species (including <i>B. fragilis), Gardnerella vaginalis</i>,<i> Peptococcus</i> species, <i>Peptostreptococcus</i> species, and <i>Cutibacterium</i> species.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, health care-associated or high-risk community-acquired infection: </b>Treatment of intra-abdominal infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>S. epidermidis, E. coli, Klebsiella</i> species, <i>Enterobacter</i> species, <i>Proteus</i> species, <i>Morganella morganii, P. aeruginosa, Citrobacter</i> species, <i>Clostridium</i> species, <i>Bacteroides</i> species (including <i>B. fragilis</i>), <i>Fusobacterium</i> species, <i>Peptococcus</i> species, <i>Peptostreptococcus</i> species, <i>Eubacterium</i> species, <i>Cutibacterium</i> species, and <i>Bifidobacterium</i> species.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia: </b>Treatment of pneumonia caused by <i>S. aureus</i> (penicillinase-producing), <i>E. coli, Klebsiella</i> species, <i>Enterobacter</i> species, <i>Haemophilus influenzae, Haemophilus parainfluenzae, Acinetobacter</i> species, and <i>Serratia marcescens</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, moderate to severe: </b>Treatment of skin and soft tissue infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), S<i>. epidermidis, E. coli, Klebsiella</i> species, <i>Enterobacter </i>species<i>, Proteus vulgaris, Providencia rettgeri, M. morganii, P. aeruginosa, Serratia</i> species, <i>Citrobacter</i> species, <i>Acinetobacter</i> species, <i>Bacteroides</i> species (including <i>B. fragilis</i>), <i>Fusobacterium</i> species, <i>Peptococcus</i> species, and <i>Peptostreptococcus</i> species.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (complicated and uncomplicated): </b>Treatment of uncomplicated and complicated urinary tract infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>E. coli, Klebsiella</i> species, <i>Enterobacter</i> species, <i>P. vulgaris, P. rettgeri, M. morganii, and P. aeruginosa.</i></p></div>
<div class="block off-label drugH1Div" id="F25726672"><span class="drugH1">Use: Off-Label: Adult</span><p>Cystic fibrosis, acute pulmonary exacerbation; Diabetic foot infection, moderate to severe; Melioidosis (Burkholderia pseudomallei infection); Mycobacterial (nontuberculous, rapidly growing) infection; Neutropenic enterocolitis (typhlitis); Neutropenic fever, high-risk patients with cancer (empiric therapy); Nocardiosis, severe; Peritonitis, treatment (patients undergoing peritoneal dialysis); Sepsis/septic shock (broad-spectrum empiric therapy, including P. aeruginosa); Skin and soft tissue necrotizing infection</p></div>
<div class="block mst drugH1Div" id="F182095"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Imipenem may be confused with ertapenem, meropenem, doripenem</p>
<p style="text-indent:-2em;margin-left:4em;">Primaxin may be confused with Premarin, Primacor</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299512"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F182036"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Imipenem may enhance the neurotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased. Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Imipenem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F182052"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;margin-left:0em;">Imipenem and cilastatin cross the placenta (Cho 1988; Heikkilä 1992)</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of imipenem/cilastatin may be altered (Heikkilä 1992).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Imipenem is not one of the preferred antibiotics for the management of cystic fibrosis in pregnant females; however, it may be used when a safer alternative is not available (Panchaud 2016).</p></div>
<div class="block brc drugH1Div" id="F3878676"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Imipenem is present in breast milk (Ito 1988; Chung 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Imipenem is not one of the preferred antibiotics used for the management of cystic fibrosis in lactating females; however, when a safer alternative is not available, imipenem is the preferred carbapenem antibiotic. Due to poor oral bioavailability, exposure to a breastfed infant is expected to be limited (Panchaud 2016).</p></div>
<div class="block dic drugH1Div" id="F182053"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F182041"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic renal, hepatic, and hematologic function tests; monitor for signs of anaphylaxis during first dose</p></div>
<div class="block pha drugH1Div" id="F182030"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules.</p></div>
<div class="block phk drugH1Div" id="F182049"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Lung: Epithelial lining fluid:plasma ratio: 44%, varies with time (van Hasselt 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (GA 31 to 42 weeks; PNA ≤10 days): Imipenem: 0.538 ± 0.105 L/kg; Cilastatin: 0.246 ± 0.05 L/kg (Freij 1985).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years: Imipenem: 0.656 ± 0.122 L/kg (Jacobs 1984).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Imipenem: ~20%; cilastatin: ~40%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Imipenem is metabolized in the kidney by dehydropeptidase I; cilastatin prevents imipenem metabolism by this enzyme.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA 31 to 42 weeks; PNA ≤10 days): Mean range: Imipenem: 1.7 to 2.4 hours; Cilastatin: 3.9 to 6.4 hours (Freij 1985).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: Imipenem: 1.2 hours (Jacobs 1984).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults (both drugs): ~60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Both drugs: Urine (~70% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F55430373"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC).</p>
<p style="text-indent:-2em;margin-left:8em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>P. aeruginosa</i>: Goal: ≥40% <i>f</i>T &gt; MIC (bactericidal) (Ong 2007).</p>
<p style="text-indent:-2em;margin-left:8em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Critically ill patients in the ICU: Minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt; 4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in patients with normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to 12 years of age: 25 mg/kg IV (15-minute infusion), single dose: Imipenem: 33.47 mg/L (Jacobs 1984).</p>
<p style="text-indent:-2em;margin-left:10em;">Adults:</p>
<p style="text-indent:-2em;margin-left:12em;">500 mg IV, single dose: Imipenem: 21 to 58 mg/L; cilastatin: 31 to 49 mg/L.</p>
<p style="text-indent:-2em;margin-left:12em;">1 g IV, single dose: Imipenem: 41 to 83 mg/L; cilastatin: 56 to 88 mg/L.</p>
<p style="text-indent:-2em;margin-left:12em;">Critical illness: 1 g every 8 hours (30-minute infusion), steady state: Imipenem: 44.2 ± 13.26 mg/L; 500 mg every 6 hours (3-hour infusion), steady state: Imipenem: 9.25 ± 3.47 mg/L (Lipš 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Minimal bacterial killing continues after imipenem concentration falls below the MIC of targeted pathogen and varies based on the organism:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. aureus</i>: 1.1 to 1.8 hours (Nadler 1989; Odenholt 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>P. aeruginosa: </i>1.2 to 2.6 hours (Nadler 1989).</p>
<p style="text-indent:-2em;margin-left:6em;">Other gram-negative organisms (eg, <i>Enterobacter cloacae, E. coli, H. influenzae, M. morganii, S. marcescens</i>)<i>: </i>≤0.4 hours (Nadler 1989; Odenholt 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F182054"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cilanem | Tienam</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dixabiox i.v. | Fada imipenem | Imipenem + cilastatina dosa | Imipenem + cilastatina norgreen | Imipenem celtyc | Imipenem cilastatin | Imipenem fabra | Imistatin | Klonam | Zienam</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin actavis | Imipenem/cilastatin aptapharma | Imipenem/cilastatin eberth | Imipenem/cilastatin hospira | Imipenem/cilastatin kabi | Imipenem/Cilastatin Sandoz | Zienam trockenstechampulle</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Primaxin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cispenam | Imbac | Iminem | Iropen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/Cilastatin fresenius kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Bacqure</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cilastem | Imecitin | Imipenem cilastatin panpharma | Imipenem/cilastatin aptapharma | Imipenem/cilastatin hospira | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Imicil | Imipenem + cilastatina | Imipenem + cilastatina sodica | Imipenem / Cilastatina | Imipenem monoidratado + cilastatina sodica | Tienam | Tiepem</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Imipenem cilastatin actavis | Imipenem cilastatin labatec | Imipenem cilastatin mepha | Tienam</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Imipenem cilastatin | Tienam</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bacqure | Imipenem and cilastatin sodium | Prepenem | Tienam</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Arzomeba | Cilastatina + imipenem | Imcibios | Imipenem + cilastatina | Imipenem / Cilastatina | Imipenem cilastina | Imipenem/cilastatina winthrop | Imipenen Cilastatina | Inem | Itixib | Tienam | Tiesilan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin aptapharma | Imipenem/cilastatin hospira | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Imipenem Cilastatin Rotexmedica | Imipenem cilastin actavis | Imipenem und Cilastatin Hospira | Imipenem und Cliastatin | Imipenem/cilastatin | Imipenem/cilastatin eberth | Imipenem/Cilastatin Hexal | Imipenem/cilastatin kabi | Imipenem/Cilastatin Noridem | Zienam</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Iminem | Imipenem cilastatin | Imlatin | Primaxin | Solmidex | Tienam | Tiesilan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Arzomeba | Bacqure | Imipen | Imipenem + cilastatina | Imipenem y cilastina | Imipenen y Cilastatina | Tienam | Tiesilan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin actavis | Imipenem/cilastatin eberth | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ayapenam | Bacqure | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/Cilastatina Actavis | Imipenem/Cilastatina Hospira | Imipenem/Cilastatina Kabi | Imipenem/Cilastatina Teva | Tienam</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Tienam</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Andatin | Imipenem/cilastatin hospira | Tienam</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imipenem Cilastatine | Imipenem cilastatine actavis | Imipenem cilastatine Gerda | Imipenem cilastatine hospira | Imipenem cilastatine Mylan | Imipenem cilastatine panpharma | Imipenem cilastatine sun | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin | Primaxin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Imicil | Imipenem+cilastatin/hospira | Imipenem+cilastatin/kabi | Imipenem/cilastatin kabi | Nimedine | Primagal | Primaxin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Prepenem | Tienam</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin kabi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cilanem | Imipenem/cilastatin aptapharma | Imipenem/cilastatin hospira | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Elastyn | Imiclast | Imitatin | Pelascap | Pelastin | Tienam | Timipen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alimpenam c | Cilanem | Cilasafe | Cilaspen | Cilaspenem | Cilaxter | Critinem | Diode ic | Emicel | I man | I Nem | Icibi | Ime Cila | Imicelum | Imicrit | Imilan | Iminem | Imiq | Imiren | Kabicilas | Larinum | Lastinem | Maxigard | Micromax | Mpenex | Nimastin | Primanat | Primapen | Sekur | Superpenem | Themizen | Zilamac | Zilonem</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Imecitin | Imipem | Imipenem cilastatin kabi | Imipenem e cilastatin hikma | Imipenem e cilastatina ranbaxy | Imipenem/Cilastatina Hospira | Tenacid | Tienam</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin | Imista | Ivnem | Premax | Tienam</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Chiecool | Imipenem/Cilastatin Sandoz | Imistan | Indast | Tienam | Tiepenem</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alimpenam c | Bacqure | Cilapen | Cispenam | Imbac | Imicil | Inno cila | Lastinem | Makcila | Maxinem | Pantin | Pelastin | Tienam</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Celinem | Cilapenem | Cilasin | Imicil kit | Imifem | Ipem q | Neopenem | Newpenem | Prepenem | Starpenem | Teonam | Tienam | Tipem</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Amanam | Cilanem | Imilastin | Imipenem and cilastatin | Tienam</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin | Imipenem/cilastatin actavis | Imipenem/cilastatin eberth | Imipenem/cilastatin ranbaxy | Nimedine | Tienam</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Tienam</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin | Imipenem/cilastatin actavis | Tienam</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bacqure | Tienam</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acigfacil | Arzomeba | Cilapenalis | Imikencil | Iminen | Imipenem Cilastatina Farmadem | Imipenem Cilastatina Provacs | Imipenem cilastina | Impicira | Sensimitina | Tienam</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Imipenem and cilastatin | Prepenem | Tienam</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bacqure</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin actavis | Imipenem/cilastatin hikma | Imipenem/Cilastatine | Imipenem/Cilastatine Fresenius Kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Andatin | Imipenem cilastatin actavis | Imipenem/cilastatin hospira | Tienam</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Imipenem+cilastatin | Primaxin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bacqure | Cistacor | Imilast | Iminen | Imipem | Imipenem + cilastatina | Inedox | Penemcil | Tienam</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hospira imipenem/cilastatin | Iminam | Prepenem | Tienam | Vexpinem 500</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cilenem | Imicid | Iminem | Prepenem | Primaxin | Stanem | Tienam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Imecitin | Imipenem + Cilastatin AptaPharma | Ransetron | Tienam | Zienam</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Imipenem and cilastatin | Primaxin | Primaxin im</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Imipenem + cilastatina | Imipenem + cilastatina generis | Imipenem + Cilastatina Hospira | Imipenem/Cilastatina Kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cilenen | Imipecil | Imipenem cilastatina icu vita | Imipenem cilastatina klonal | Imipenem cilastatina libra | Imipenem cilastatina nortelab | Imipenem cilastatina pharmavial | Imipenem cilastatina prosalud | Imipenem cilastatina richet | Imipenem cilastatina suanfarma | Imipinem cilastatina fusa | Miniem | Zienam</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Imista | Lastinem | Tienam</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cilopen | Imipenem/cilastatin atb | Imipenem/cilastatin hospira | Imipenem/cilastatin kabi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aquapenem | Bactopenem | Cilapenem | Cilaspen | Grimipenem | Imipenem + Cilastatin | Imipenem + cilastatin jodas | Imipenem and cilastatin | Imipenem and cilastatin spenser | Imipenem+cilastatin | Imipenem+cilastatin vial | Imipenem/cilastatin kabi | Tielvel | Tienam | Tiepenem</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ivnem | Lastinem | Primagal | Tienam | Zaynam</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Imipenem/cilastatin actavis | Imipenem/Cilastatin fresenius kabi | Imipenem/cilastatin hospira | Tienam</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Imipenem and cilastatin hospira | Tienam</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Conet | Imipenem/Cilastatin Apta | Imipenem/cilastatin kabi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Imecitin | Imipenem/cilastatin hospira | Imipenem/cilastatin kabi | Tienam</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cilapenem | Imepen | Sianem | Simipenam | Tienam</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Primagal | Synergic | Tienam</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cilapem | Imicil | Silanem | Tienam</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bestnem | Cipenem | Culin | Imipenem/cilastatin | Penem | Supernem | Teaname | Tienam | Younam</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Brupenem | Cilpen | Imibacid | Imifors | Imipenem/cilastatin | Inemplus | Mixacil | Prepenem | Sinerpen | Supranem | Tienam | Vipenem</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Bacqure | Inemplus | Lastinem | Zemilast</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Imipecil | Imipen | Imipenem ION | Inedox | Zienam</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Imidex | Imipenem + cilastatina | Lastinem | Menepim | Penastim</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Itaban | Raxadin | Tadifs | Vicimlastatin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cilapen | IMIPENEM/CILASTATIN FRESENIUS | Sepencil | Tiasep | Tienam</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bacqure | Lastinem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31487382">
<a name="31487382"></a>Abbott L, Plummer A, Hoo ZH, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD006682. doi:10.1002/14651858.CD006682.pub6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/31487382/pubmed" id="31487382" target="_blank">31487382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and sepsis working group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17366527">
<a name="17366527"></a>Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. <i>Pediatr Blood Cancer</i>. 2007;49(6):786-792. doi:10.1002/pbc.21179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/17366527/pubmed" id="17366527" target="_blank">17366527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2211452">
<a name="2211452"></a>Alarabi AA, Cars O, Danielson BG, Salmonson T, Wikström B. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. <i>J Antimicrob Chemother</i>. 1990;26(1):91-98. doi:10.1093/jac/26.1.91<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2211452/pubmed" id="2211452" target="_blank">2211452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7612739">
<a name="7612739"></a>Anwar N, Merchant M, Were T, Tooth A, Uttley L, Gokal R. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. <i>Perit Dial Int.</i> 1995;15(2):167-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/7612739/pubmed" id="7612739" target="_blank">7612739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8741235">
<a name="8741235"></a>Balfour JA, Bryson HM, and Brogden RN, “Imipenem/Cilastatin: An Update of Its Antibacterial Activity, Pharmacokinetics, and Therapeutic Efficacy in the Treatment of Serious Infections,” <i>Drugs</i>, 1996, 51(1):99-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/8741235/pubmed" id="8741235" target="_blank">8741235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.2023">
<a name="Barshak.2023"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8858691">
<a name="8858691"></a>Blumer JL, "Pharmacokinetic Determinants of Carbapenem Therapy in Neonates and Children," <i>Pediatr Infect Dis J</i>, 1996, 15(8):733-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/8858691/pubmed" id="8858691" target="_blank">8858691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bomback.1995">
<a name="Bomback.1995"></a>Bomback T, Sesin GP, and Mucciardi N, “Possible Imipenem/Cilastatin-Induced Aplastic Anemia,” <i>Pharm Therapeut</i>, 1995, 20(5):293-302.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10885853">
<a name="10885853"></a>Böswald M, Döbig C, Krüger J, et al. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. <i>Infection</i>. 1999;27(4-5): 299-304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/10885853/pubmed" id="10885853" target="_blank">10885853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30528370">
<a name="30528370"></a>Bricheux A, Lenggenhager L, Hughes S, Karmime A, Lescuyer P, Huttner A. Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study. <i>Clin Microbiol Infect</i>. 2019;25(3):383.e1-383.e4. doi:10.1016/j.cmi.2018.11.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/30528370/pubmed" id="30528370" target="_blank">30528370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burkart.2022">
<a name="Burkart.2022"></a>Burkart JM. Microbiology and therapy of peritonitis in peritoneal dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36979919">
<a name="36979919"></a>Butranova OI, Ushkalova EA, Zyryanov SK, Chenkurov MS. Developmental pharmacokinetics of antibiotics used in neonatal ICU: focus on preterm infants. <i>Biomedicines</i>. 2023;11(3):940. doi:10.3390/biomedicines11030940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/36979919/pubmed" id="36979919" target="_blank">36979919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22690308">
<a name="22690308"></a>Caselli D, Paolicchi O. Empiric antibiotic therapy in a child with cancer and suspected septicemia. <i>Pediatr Rep</i>. 2012;4(1):e2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22690308/pubmed" id="22690308" target="_blank">22690308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2016">
<a name="CDC.2016"></a>Centers for Disease Control and Prevention. Nocardiosis information for healthcare workers. <a href="https://www.cdc.gov/nocardiosis/health-care-workers/" target="_blank">https://www.cdc.gov/nocardiosis/health-care-workers/</a> Updated March 30, 2016. Accessed September 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2055813">
<a name="2055813"></a>Chan CY, Lai KN, Lam AW, Li PK, Chung WW, French GL. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. <i>J Antimicrob Chemother</i>. 1991;27(2):225-232. doi:10.1093/jac/27.2.225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2055813/pubmed" id="2055813" target="_blank">2055813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25102221">
<a name="25102221"></a>Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant <i>Staphylococcus aureus</i>, gram-negative bacteria, and multiple infections. <i>Ann Am Thorac Soc</i>. 2014;11(7):1120-1129. doi:10.1513/AnnalsATS.201402-050AS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/25102221/pubmed" id="25102221" target="_blank">25102221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3062206">
<a name="3062206"></a>Cho N, Fukunaga K, Kunii K, Kobayashi I, Tezuka K. Studies on imipenem/cilastatin sodium in the perinatal period [in Japanese]. <i>Jpn J Antibiot</i>. 1988;41(11):1758-1773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3062206/pubmed" id="3062206" target="_blank">3062206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31599774">
<a name="31599774"></a>Corcione S, Lupia T, Maraolo AE, Pinna SM, Gentile I, De Rosa FG. Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship.<i> Curr Opin Infect Dis</i>. 2019;32(6):663-673. doi:10.1097/QCO.0000000000000598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/31599774/pubmed" id="31599774" target="_blank">31599774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Currie.2021">
<a name="Currie.2021"></a>Currie B, Anstey NM. Melioidosis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14516149">
<a name="14516149"></a>Currie BJ. Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions. <i>Eur Respir J.</i> 2003;22(3):542-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/14516149/pubmed" id="14516149" target="_blank">14516149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32628747">
<a name="32628747"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. <i>Clin Infect Dis</i>. 2020;71(4):e1-e36. doi:10.1093/cid/ciaa241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/32628747/pubmed" id="32628747" target="_blank">32628747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34791295">
<a name="34791295"></a>Dao K, Fuchs A, André P, et al. Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. <i>J Antimicrob Chemother</i>. 2022;77(2):457-465. doi:10.1093/jac/dkab394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/34791295/pubmed" id="34791295" target="_blank">34791295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30962334">
<a name="30962334"></a>Dong L, Zhai XY, Yang YL, et al. Population pharmacokinetics and dosing optimization of imipenem in children with hematological malignancies. <i>Antimicrob Agents Chemother</i>. 2019;63(6):e00006-19. doi:10.1128/AAC.00006-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/30962334/pubmed" id="30962334" target="_blank">30962334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11106223">
<a name="11106223"></a>Döring G, Conway SP, Heijerman HG, et al, "Antibiotic Therapy Against <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis: A European Consensus," <i>Eur Respir J</i>, 2000, 16(4):749-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/11106223/pubmed" id="11106223" target="_blank">11106223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20104991">
<a name="20104991"></a>Erbey F, Bayram I, Yilma S, Tanyeli A. Imipenem in the treatment of febrile neutropenic children. <i>Asian Pac J Cancer Prev</i>. 2009;10(5):921-924.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20104991/pubmed" id="20104991" target="_blank">20104991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Med</i>. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Finch.1986">
<a name="Finch.1986"></a>Finch RG, Craddock C, Kelly J, et al. Pharmacokinetic Studies of Imipenem/Cilastatin in Elderly Patients. <i>J Antimicrob Chemother</i>. 1986;18(suppl E):103-107.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15917542">
<a name="15917542"></a>Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. <i>Antimicrob Agents Chemother.</i> 2005;49(6):2421-2428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/15917542/pubmed" id="15917542" target="_blank">15917542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):i1-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19729669">
<a name="19729669"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. <i>Am J Respir Crit Care Med.</i> 2009;180(9):802-808. doi:10.1164/rccm.200812-1845PP<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19729669/pubmed" id="19729669" target="_blank">19729669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3859242">
<a name="3859242"></a>Freij BJ, McCracken GH Jr, Olsen KD, et al, "Pharmacokinetics of Imipenem-Cilastatin in Neonates," <i>Antimicrob Agents Chemother</i>, 1985, 27(4):431-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3859242/pubmed" id="3859242" target="_blank">3859242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3859216">
<a name="3859216"></a>Gibson TP, Demetriades JL, Bland JA. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. <i>Am J Med</i>. 1985;78(6A):54-61. doi:10.1016/0002-9343(85)90102-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3859216/pubmed" id="3859216" target="_blank">3859216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci</i>. 2018;25(1):3-16. doi:10.1002/jhbp.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34469706">
<a name="34469706"></a>Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respir Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/34469706/pubmed" id="34469706" target="_blank">34469706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8075257">
<a name="8075257"></a>Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. <i>Clin Infect Dis</i>. 1994;18(5):683-693. doi:10.1093/clinids/18.5.683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/8075257/pubmed" id="8075257" target="_blank">8075257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Griffith.2020">
<a name="Griffith.2020"></a>Griffith DE. Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.2022">
<a name="Gupta.2022"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1482132">
<a name="1482132"></a>Heikkilä A, Renkonen OV, Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. <i>Antimicrob Agents Chemother</i>. 1992;36(12):2652-2655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/1482132/pubmed" id="1482132" target="_blank">1482132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19072244">
<a name="19072244"></a>High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(2):149-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19072244/pubmed" id="19072244" target="_blank">19072244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28919718">
<a name="28919718"></a>Ibrahim MM, Tammam TF, Ebaed MED, Sarhan HA, Gad GF, Hussein AK. Extended infusion versus intermittent infusion of imipenem in the treatment of ventilator-associated pneumonia. <i>Drug Des Devel Ther</i>. 2017;11:2677-2682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/28919718/pubmed" id="28919718" target="_blank">28919718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Imipenem and cilastatin [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Imipenem and cilastatin for injection USP [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547571">
<a name="16547571"></a>Inglis TJ, Rolim DB, Rodriguez JL. Clinical guideline for diagnosis and management of melioidosis. <i>Rev Inst Med Trop Sao Paulo.</i> 2006;48(1):1-4. doi:10.1590/s0036-46652006000100001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/16547571/pubmed" id="16547571" target="_blank">16547571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3210308">
<a name="3210308"></a>Ito K, Izumi K, Takagi H, Tamaya T, Hayasaki M. Fundamental and clinical evaluation of imipenem/cilastatin sodium in the perinatal period [in Japanese]. <i>Jpn J Antibiot</i>. 1988;41(11):1778-1785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3210308/pubmed" id="3210308" target="_blank">3210308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6594492">
<a name="6594492"></a>Jacobs RF, Kearns GL, Trang JM, et al. Single-dose pharmacokinetics of imipenem in children. <i>J Pediatr.</i> 1984;105(6):996-1001. doi:10.1016/s0022-3476(84)80098-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/6594492/pubmed" id="6594492" target="_blank">6594492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25727953">
<a name="25727953"></a>Jaruratanasirikul S, Wongpoowarak W, Jullangkoon M, Samaeng M. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia. <i>J Pharmacol Sci.</i> 2015;127(2):164-169. doi:10.1016/j.jphs.2014.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/25727953/pubmed" id="25727953" target="_blank">25727953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. Published online July 14, 2016. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.1">
<a name="Kanj.1"></a>Kanj SS, Sexton DJ. Principles of antimicrobial therapy of Pseudomonas aeruginosa infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.2">
<a name="Kanj.2"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa bacteremia and endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.3">
<a name="Kanj.3"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa skin and soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.2022">
<a name="Klompas.2022"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1929334">
<a name="1929334"></a>Konishi K, Suzuki H, Saruta T, et al. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. <i>Antimicrob Agents Chemother</i>. 1991;35(8):1616-1620. doi:10.1128/AAC.35.8.1616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/1929334/pubmed" id="1929334" target="_blank">1929334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36689694">
<a name="36689694"></a>Lehrnbecher T, Robinson PD, Ammann RA. Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update. <i>J Clin Oncol</i>. 2023;41(9):1774-1785. doi:10.1200/JCO.22.02224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/36689694/pubmed" id="36689694" target="_blank">36689694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1926901">
<a name="1926901"></a>Leo RJ and Ballow CH, “Seizure Activity Associated With Imipenem Use: Clinical Case Reports and Review of the Literature,” <i>DICP</i>, 1991, 25(4):351-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/1926901/pubmed" id="1926901" target="_blank">1926901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26919659">
<a name="26919659"></a>Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy.<i> J Clin Pharmacol</i>. 2016;56(10):1277-1287. doi:10.1002/jcph.727<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/26919659/pubmed" id="26919659" target="_blank">26919659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628102">
<a name="20628102"></a>Li PK, Szeto CC, Piraino B, et al; International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. <i>Perit Dial Int.</i> 2010;30(4):393-423. doi:10.3747/pdi.2010.00049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20628102/pubmed" id="20628102" target="_blank">20628102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30310294">
<a name="30310294"></a>Lim TP, Wang R, Poh GQ, et al. Integrated pharmacokinetic-pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. <i>Infect Drug Resist.</i> 2018;11:1591-1596. doi:10.2147/IDR.S168191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/30310294/pubmed" id="30310294" target="_blank">30310294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25216543">
<a name="25216543"></a>Lipš M, Siller M, Strojil J, Urbánek K, Balík M, Suchánková H. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. <i>Int J Antimicrob Agents</i>. 2014;44(4):358-362. doi:10.1016/j.ijantimicag.2014.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/25216543/pubmed" id="25216543" target="_blank">25216543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012;54(12):e132-e173. doi:10.1093/cid/cis346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077618">
<a name="31077618"></a>Longworth SA, Daly JS; AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13588. doi:10.1111/ctr.13588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/31077618/pubmed" id="31077618" target="_blank">31077618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7977477">
<a name="7977477"></a>Lui SF, Cheng AB, Leung CB, Wong KC, Li PK, Lai KN. Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. <i>Am J Nephrol.</i> 1994;14(3):182-186. doi:10.1159/000168711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/7977477/pubmed" id="7977477" target="_blank">7977477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987068">
<a name="29987068"></a>Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int.</i> 2018;38(4):309-310. doi:10.3747/pdi.2018.00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/29987068/pubmed" id="29987068" target="_blank">29987068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt).</i> 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America.<i> Clin Infect Dis.</i> 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2020a">
<a name="Moehring.2020a"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2020b">
<a name="Moehring.2020b"></a>Moehring R, Sarubbi C. Prolonged infusions of beta-lactam antibiotics. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 1, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8430678">
<a name="8430678"></a>Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. <i>Am J Kidney Dis</i>. 1993;21(2):172-179. doi:10.1016/s0272-6386(12)81089-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/8430678/pubmed" id="8430678" target="_blank">8430678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2509416">
<a name="2509416"></a>Nadler HL, Pitkin DH, Sheikh W. The postantibiotic effect of meropenem and imipenem on selected bacteria. <i>J Antimicrob Chemother.</i> 1989;24(suppl A):225-231. doi:10.1093/jac/24.suppl_a.225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2509416/pubmed" id="2509416" target="_blank">2509416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7716590">
<a name="7716590"></a>Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. <i>South Med J.</i> 1995;88(4):397-404. doi:10.1097/00007611-199504000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/7716590/pubmed" id="7716590" target="_blank">7716590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34588142">
<a name="34588142"></a>Nicholson TT, Smith A, McKone EF, Gallagher CG. Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: a systematic review. <i>J Cyst Fibros</i>. 2022;21(4):562-573. doi:10.1016/j.jcf.2021.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/34588142/pubmed" id="34588142" target="_blank">34588142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7791421">
<a name="7791421"></a>Norrby SR, “Carbapenems,” <i>Med Clin North Am</i>, 1995, 79(4):745-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/7791421/pubmed" id="7791421" target="_blank">7791421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ODonovan.1995">
<a name="ODonovan.1995"></a>O'Donovan CA, White ML, Cheung A, et al, “Seizure Incidence With Imipenem Use at VA Hospital,” <i>Hosp Formul</i>, 1995, 30:172-5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9736564">
<a name="9736564"></a>Odenholt I, Löwdin E, Cars O. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 1998;42(9):2365-2370. doi:10.1128/AAC.42.9.2365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/9736564/pubmed" id="9736564" target="_blank">9736564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16930925">
<a name="16930925"></a>Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against <i>Pseudomonas aeruginosa</i> expressing MexA-MexB-OprM efflux pumps. <i>Diagn Microbiol Infect Dis</i>. 2007;57(2):153-161. doi:10.1016/j.diagmicrobio.2006.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/16930925/pubmed" id="16930925" target="_blank">16930925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28500792">
<a name="28500792"></a>Oriol I, Sabé N, Simonetti AF, et al. Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study.<i> Transpl Int.</i> 2017;30(9):903-913. doi:10.1111/tri.12984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/28500792/pubmed" id="28500792" target="_blank">28500792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658169">
<a name="30658169"></a>Ott SR, Meier N, Kolditz M, et al; OPINION Study Group. Pulmonary nocardiosis in Western Europe-clinical evaluation of 43 patients and population-based estimates of hospitalization rates. <i>Int J Infect Dis</i>. 2019;81:140-148. doi:10.1016/j.ijid.2018.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/30658169/pubmed" id="30658169" target="_blank">30658169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19273670">
<a name="19273670"></a>Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant <i>Pseudomonas aeruginosa</i>. <i>Antimicrob Agents Chemother.</i> 2009;53(5):1983-1986. doi:10.1128/AAC.01535-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19273670/pubmed" id="19273670" target="_blank">19273670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26942733">
<a name="26942733"></a>Panchaud A, Di Paolo ER, Koutsokera A, et al. Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients. <i>Respiration</i>. 2016;91(4):333-348. doi:10.1159/000444088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/26942733/pubmed" id="26942733" target="_blank">26942733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16344285">
<a name="16344285"></a>Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. <i>J Antimicrob Chemother.</i> 2006;57(2):176-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/16344285/pubmed" id="16344285" target="_blank">16344285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2023">
<a name="Pemberton.2023"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Primaxin.1">
<a name="Primaxin.1"></a>Primaxin (imipenem and cilastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Primaxin.2">
<a name="Primaxin.2"></a>Primaxin (imipenem and cilastatin) injection [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32561442">
<a name="32561442"></a>Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. <i>Chest</i>. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/32561442/pubmed" id="32561442" target="_blank">32561442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2393278">
<a name="2393278"></a>Reed MD, Kliegman RM, Yamashita TS, et al, "Clinical Pharmacology of Imipenem and Cilastatin in Premature Infants During the First Week of Life," <i>Antimicrob Agents Chemother</i>, 1990, 34(6):1172-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2393278/pubmed" id="2393278" target="_blank">2393278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1766707">
<a name="1766707"></a>Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. <i>Pediatr Infect Dis J</i>. 1991;10(12):918-923.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/1766707/pubmed" id="1766707" target="_blank">1766707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis</i>. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19832720">
<a name="19832720"></a>Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. <i>Clin Microbiol Infect.</i> 2010;16(8):1252-1257. doi:10.1111/j.1469-0691.2009.03067.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19832720/pubmed" id="19832720" target="_blank">19832720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28484510">
<a name="28484510"></a>Sartelli M, Catena F, Abu-Zidan FM, et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. <i>World J Emerg Surg.</i> 2017;12:22. doi:10.1186/s13017-017-0132-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/28484510/pubmed" id="28484510" target="_blank">28484510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schmidt.2020">
<a name="Schmidt.2020"></a>Schmidt GA, Mandel J. Evaluation and management of suspected sepsis and septic shock in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 1, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-simon.2021">
<a name="simon.2021"></a>Simon RH. Cystic fibrosis: treatment of acute pulmonary exacerbation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10476746">
<a name="10476746"></a>Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. <i>Clin Infect Dis</i>. 1999;29(2):381-387. doi:10.1086/520219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/10476746/pubmed" id="10476746" target="_blank">10476746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28575389">
<a name="28575389"></a>Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. <i>J Antimicrob Chemother.</i> 2017;72(9):2616-2626. doi:10.1093/jac/dkx139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/28575389/pubmed" id="28575389" target="_blank">28575389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3377464">
<a name="3377464"></a>Somani P, Freimer EH, Gross ML, Higgins JT Jr. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 1988;32(4):530-534. doi:10.1128/AAC.32.4.530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3377464/pubmed" id="3377464" target="_blank">3377464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2020">
<a name="Spelman.2020"></a>Spelman D. Treatment of nocardiosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3132441">
<a name="3132441"></a>Strandvik B, Malmborg AS, Bergan T, Michalsen H, Storrøsten OT, Wretlind B. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. <i>J Antimicrob Chemother</i>. 1988;21(4):471-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3132441/pubmed" id="3132441" target="_blank">3132441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32986699">
<a name="32986699"></a>Sullivan RP, Marshall CS, Anstey NM, Ward L, Currie BJ. 2020 review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. <i>PLoS Negl Trop Dis</i>. 2020;14(9):e0008659. doi:10.1371/journal.pntd.0008659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/32986699/pubmed" id="32986699" target="_blank">32986699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987069">
<a name="29987069"></a>Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter-related infections-in reply. <i>Perit Dial Int.</i> 2018;38(4):311-312. doi:10.3747/pdi.2018.00046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/29987069/pubmed" id="29987069" target="_blank">29987069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-Lactamase-producing Enterobacterales, Carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. <i>Clin Infect Dis</i>. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9420033">
<a name="9420033"></a>Tegeder I, Bremer F, Oelkers R, et al, “Pharmacokinetics of Imipenem-Cilastatin in Critically Ill Patients Undergoing continuous Veno-Venous Hemofiltration,” <i>Antimicrob Agents Chemother</i>, 1997, 41(12):2640-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/9420033/pubmed" id="9420033" target="_blank">9420033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3470047">
<a name="3470047"></a>Toon S, Hopkins KJ, Garstang FM, et al, “Pharmacokinetics of Imipenem and Cilastatin After Their Simultaneous Administration to the Elderly,” <i>Br J Clin Pharmacol</i>, 1987, 23(2):143-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3470047/pubmed" id="3470047" target="_blank">3470047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trissel.1999">
<a name="Trissel.1999"></a>Trissel LA, Gilbert DL, and Wolkin AC, "Compatibility of Docetaxel With Selected Drugs During Simulated Y-Site Administration," <i>Int J Pharmaceut Compound</i>, 1999, 3(3):241-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer W. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20835502">
<a name="20835502"></a>Ulug M, Gedik E, Girgin S, et al, “Pyogenic Liver Abscess Caused By Community-Acquired Multidrug Resistance <i>Pseudomonas aeruginosa</i>,” <i>Braz J Infect Dis</i>, 2010, 14(3):218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20835502/pubmed" id="20835502" target="_blank">20835502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27139161">
<a name="27139161"></a>VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. <i>J Cyst Fibros</i>. 2016;15(6):783-790. doi:10.1016/j.jcf.2016.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/27139161/pubmed" id="27139161" target="_blank">27139161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26852277">
<a name="26852277"></a>van Hasselt JG, Rizk ML, Lala M, et al. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. <i>Br J Clin Pharmacol.</i> 2016;81(6):1113-1123. doi:10.1111/bcp.12901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/26852277/pubmed" id="26852277" target="_blank">26852277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3469184">
<a name="3469184"></a>Verbist L, Verpooten GA, Giuliano RA, et al. Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure. <i>J Antimicrob Chemother</i>. 1986;18(suppl E):115-120. doi:10.1093/jac/18.supplement_e.115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3469184/pubmed" id="3469184" target="_blank">3469184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12121900">
<a name="12121900"></a>Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). <i>Antimicrob Agents Chemother</i>. 2002;46(8):2327-2332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/12121900/pubmed" id="12121900" target="_blank">12121900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.2022">
<a name="Vollmer.2022"></a>Vollmer CM Jr, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19744230">
<a name="19744230"></a>Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. <i>Pediatr Int</i>. 2010;52(2):262-267. doi:10.1111/j.1442-200X.2009.02952.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19744230/pubmed" id="19744230" target="_blank">19744230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al, "Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update," <i>Perit Dial Int</i>, 2012, 32(Suppl 20):32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.2020">
<a name="Weintrob.2020"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12767750">
<a name="12767750"></a>White NJ. Melioidosis. <i>Lancet</i>. 2003;361(9370):1715-1722. doi: 10.1016/s0140-6736(03)13374-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/12767750/pubmed" id="12767750" target="_blank">12767750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22970946">
<a name="22970946"></a>Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. <i>N Engl J Med</i>. 2012;367(11):1035-1044. doi:10.1056/NEJMra1204699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22970946/pubmed" id="22970946" target="_blank">22970946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29388572">
<a name="29388572"></a>Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. <i>Nat Rev Dis Primers</i>. 2018;4:17107. doi:10.1038/nrdp.2017.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/29388572/pubmed" id="29388572" target="_blank">29388572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22469352">
<a name="22469352"></a>Wilson JW. Nocardiosis: updates and clinical overview. <i>Mayo Clin Proc</i>. 2012;87(4):403-407. doi:10.1016/j.mayocp.2011.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22469352/pubmed" id="22469352" target="_blank">22469352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.2020">
<a name="Wingard.2020"></a>Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematologic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WongKeeSong.2020">
<a name="WongKeeSong.2020"></a>Wong Kee Song L-M, Marcon NE. Neutropenic enterocolitis (typhlitis). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis.</i> 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2254575">
<a name="2254575"></a>Yoshikawa TT, “Antimicrobial Therapy for the Elderly Patient,” <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2254575/pubmed" id="2254575" target="_blank">2254575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22877766">
<a name="22877766"></a>Yoshizawa K, Ikawa K, Ikeda K, Kumon H, Ohge H, Morikawa N. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data. <i>Int J Antimicrob Agents</i>. 2012;40(5):427-433. doi:10.1016/j.ijantimicag.2012.06.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22877766/pubmed" id="22877766" target="_blank">22877766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23676856">
<a name="23676856"></a>Yoshizawa K, Ikawa K, Ikeda K, Ohge H, Morikawa N. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. <i>Pediatr Infect Dis J</i>. 2013;32(11):1208-1216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/23676856/pubmed" id="23676856" target="_blank">23676856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19670912">
<a name="19670912"></a>Zhanel GG, Ketter N, Rubinstein E, et al, “Overview of Seizure-Inducing Potential of Doripenem,” <i>Drug Safety</i>, 2009, 32(9):709-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19670912/pubmed" id="19670912" target="_blank">19670912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17488146">
<a name="17488146"></a>Zhanel GG, Wiebe R, Dilay L, et al, “Comparative Review of the Carbapenems,” <i>Drugs</i>, 2007, 67(7):1027-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/17488146/pubmed" id="17488146" target="_blank">17488146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911974">
<a name="22911974"></a>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatr Pulmonol</i>. 2012;47(12):1147-1158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22911974/pubmed" id="22911974" target="_blank">22911974</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8553 Version 276.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
